Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

X
Trial Profile

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy; Familial amyloid neuropathy; Transthyretin-related hereditary amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 24 Jan 2023 Results assessing effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis, published in the European Journal of Heart Failure.
    • 29 Aug 2022 Results of pooled analysis assessing quantitative effect of patisiran and vutrisiran on orthostatic hypotension in patients with hATTR amyloidosis with polyneuropathy presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
    • 17 May 2021 Results of post-hoc analysis presented at the 70th Annual Scientific Session of the American College of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top